Drugs / Imprime PGG
Imprime PGG
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02132403 | Aug 2014 → Apr 2015 | malignant pancreatic neoplasm | University of Illinois at Chicago | Terminated | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03555149 | Sep 2018 → Sep 2022 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03003468 | Jul 2017 → Nov 2021 | non-small cell lung carcinoma | Lawrence Feldman, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01269385 | Jan 2011 → Jun 2014 | B-cell chronic lymphocytic leukemia | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00545545 | Oct 2007 → Dec 2009 | colorectal carcinoma | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05159778 | Nov 2021 → Mar 2023 | breast cancer | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04995094 | Aug 2021 → Feb 2023 | cutaneous melanoma | HiberCell, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03246685 | Nov 2017 → Apr 2018 | head and neck squamous cell carcinoma | HiberCell, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02981303 | Feb 2017 → Dec 2020 | melanoma, triple-negative breast carcinoma | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02086175 | Dec 2014 → Jul 2019 | indolent B-cell non-Hodgkin lymphoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00874848 | Aug 2009 → Nov 2012 | non-small cell lung carcinoma | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00874107 | Jun 2009 → Apr 2016 | non-small cell lung carcinoma | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01309126 | Apr 2011 → Feb 2017 | colorectal cancer | HiberCell, Inc. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00542464 Comparator | May → Sep 2006 | — | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00542217 Comparator | Dec 2005 → Apr 2006 | — | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00542529 Comparator | Nov → Dec 2006 | — | HiberCell, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imprime PGG | “Imprime PGG 2 mg/kg IV on Days 1, 8, 15 for Cycles 1-4” NCT03003468 ↗ |
| Known as | BTH1677 | “A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and...” PMID 28303530 ↗ Mar 2017 |
| Known as | imprime | “Imprime PGG (imprime), a pathogen-associated molecular pattern (PAMP), through pattern recognition receptors, successfully illicit a broad-based innate immune response in...” PMID 39670007 ↗ Nov 2024 |
| Known as | PGG beta-glucan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01269385 ↗ |
| Modality | Other / unclassified | “Imprime PGG, a glucan contained in yeast” NCT02132403 ↗ |
| Route | Intravenous | “single intravenous dose of Imprime PGG when administered to healthy adult subjects” NCT00542217 ↗ |